Vertex Pharmaceuticals Inc (VRTX)

[surf1944]

4:03PM Vertex Pharm: 75% of treatment-naive patients with chronic hepatitis C achieve SVR (Viral Cure) with Telaprevir-Based treatment in phase 3 trial (VRTX) 33.94 -0.31 : Co announced that 75% of people chronically infected with genotype 1 hepatitis C virus achieved a sustained viral response after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial. The safety and tolerability profile of telaprevir in the ADVANCE trial was consistent with the profile reported in Phase 2 studies, with an improvement in treatment discontinuation rates due to adverse events